CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today provided an update on CUDC-101 and other preclinical drug candidates under its Targeted Cancer Drug Development Platform. The Company is currently developing a number of small molecule multi-target inhibitor drug compounds, including CUDC-101. Each compound is designed to inhibit one or more validated cancer targets, such as Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF and others along with inhibition of histone deacetylase, or HDAC, a validated non-kinase cancer target.
